Psychedelics and psychiatric disorders: A emerging role
European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation
A non-systematic review of recent clinical trials indicates that classic psychedelics (LSD, psilocybin, mescaline) and entactogens (MDMA) show promise for treating psychiatric disorders. In supportive settings with psychotherapy, psilocybin produces immediate and lasting antidepressant and anxiolytic effects, including in patients with life-threatening cancer. LSD may reduce anxiety and have anti-addictive properties. MDMA is effective for PTSD. Psychedelics are generally well-tolerated, with transient anxiety, headaches, nausea, and mild cardiovascular changes as common adverse effects; no persistent psychosis or suicidality has been demonstrated. Further evidence is needed to confirm therapeutic potential.